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American College of Cardiology (ACC). The STS/ACC
TVT registry (NCT01737528) was developed in close
collaboration with the Food and Drug Administration (FDA),
the Center for Medicare and Medicaid Services (CMS), and
the Duke Clinical Research Institute. The TVT registry will
have multiple unique characteristics, partnerships, and appli-
cations that represent a paradigm shift in the introduction
and on-going evaluation of new medical device technology
(Table 1).
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Abbreviations
and Acronyms
ACC = American College of
Cardiology
CMS = Center for Medicare
and Medicaid Services
FDA = Food and Drug
Administration
IDE = investigational device
exemption
NCD = national coverage
decision
NCDR = National
Cardiovascular Data
Registry
PAS = post-approval study
RCT = randomized clinical
trial
STS = Society of Thoracic
Surgeons
TAVR = transcatheter aortic
valve replacement
TVT = transcatheter valve
therapy
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communication among key stakeholders.
The TVT registry was publicly proposed by professional
society leadership with the endorsement of the FDA and panel
members at the FDA Cardiovascular Circulatory Device
Expert Panel meeting in July 2011. It became operational on
December 1, 2011.
Why We Need a TVT Registry
The FDA is the primary authority in the United States to
regulate medical devices and is required by law to provide
“reasonable assurance of safety and effectiveness.” Once regu-
latory approval of a medical device has been granted, post-
market surveillance is performed to ensure that safe and
effective use of the device continues in the general population.
However, the infrastructure for gathering and analyzing
device use in the U.S population has been problematic and
inadequate. There have been calls for the “professional
societies, the medical device industry, and the FDA to
mobilize available resources to improve post-market surveil-
lance” (1,2).
Transcatheter aortic valve replacement (TAVR) for aortic
stenosis using the Sapien valve from Edwards Lifesciences,
Inc., has received FDA approval for patients considered
inoperable for surgery. On June 13, 2012, an FDA Advisory
Panel voted in favor of extending approval of the Sapien
technology to high-risk patients including the use of the
transapical approach in addition to the transfemoral route of
vascular access for device delivery (3). Full FDA approval
was subsequently announced (4).
Other transcatheter therapies for valvular heart disease
are being developed and the TVT registry has been designed
to facilitate their incorporation. The process of adding new
technologies, such as transcatheter mitral repair technology,
involves signiﬁcant planning including identifying data
elements that must be captured in a fashion that is stan-
dardized, well-deﬁned, and harmonized with the clinical
trials leading to regulatory approval.
The introduction of new treatment options presents
challenges that are magniﬁed when the therapy represents
a substantial transformation of both patient care and the
process of care to deliver the new therapy. Rational disper-
sion of TAVR into centers with sufﬁcient experience and
patient volume may maintain the reported results of the
PARTNER trial in inoperable and/or high-risk patients
with aortic stenosis (5). An expert consensus document
on transcatheter valve therapy has outlined the initial
technology, the targeted patient population, the multidisci-
plinary heart team, the specialized facilities needed, and the
critical need for a new type of device registry (6). Some of
the proposed uses of the registry are described in Table 2.
The Center for Devices and Radiological Health at the
FDA has embarked on a substantial effort to strengthen post-
market device surveillance. They and others have encouraged
the use of professional clinical registries for post-approvalstudies (7,8). The TVT registry
will provide the data gathering
and analysis infrastructure to en-
able comprehensive monitoring
of device safety and performance
throughout the device life cycle in
all patients being treated with this
technology. TheTVT registrywill
also incorporate “unique device
identiﬁers” being introduced in
2013 by the FDAas another effort
to improve the safe and effective
use of medical devices (9).
When new and potentially
high-risk technologies come to
market, the FDA mandates the
medical device companies to
carry out PAS. Traditionally,
manufacturers have devoted con-
siderable effort and expense to
develop a registry to fulﬁll PAS
requirements that is often created
as a stand-alone project, uses
separate data elements and
endpoints, and has little coordination with other registry
efforts. This has led to predictable inconsistencies in cardio-
vascular data reporting and safety surveillance efforts.
Furthermore, industry studies have typically not been open
to independent data analysis, and potential conﬂicts of
interest exist when a manufacturer conducts studies of its
own device.
The TVT registry represents a new model combining
the needs of the medical device industry, regulatory and
reimbursement agencies, clinicians, hospitals, patients,
researchers, and professional societies. The STS National
Database and the ACC’s National Cardiovascular Data
Registry (NCDR) have the ability to coordinate the devel-
opment and execution of this national registry and have
developed other mature national registries with well-deﬁned
protocols for data collection and audits to ensure high quality.
Unique and Innovative Aspects of the TVT Registry
The TVT registry will have multiple innovations.
Immediate focus on critical issues. Initial TAVR clinical
trials and FDA panel experts have identiﬁed the risk of
stroke, paravalvular regurgitation, outcomes differences
between sexes, vascular complications, and device durability
as key issues. The TVT registry has been designed to further
clarify these issues.
Long-term and quality-of-life outcomes. The TVT
registry will be linked to CMS claims data to evaluate
longitudinal patient outcomes, including hospitalizations
and survival. This strategy has been successfully used by the
STS and NCDR registries to examine long-term coronary
revascularization outcomes (10–12). Moreover, after the
Table 2
Major Questions and Applications Potentially
Addressed by the Transcatheter Valve
Therapy Registry
Patient selection and outcomes in different groups
 Evolving patient selection criteria. Will these closely match those enrolled in
pivotal randomized clinical trials?
 The impact of deﬁned “off-label” applications on patient outcomes and can
“coverage with evidence development” be the model applied to these patient
groups?
 The balance of risks and beneﬁts in different patient groups. What are the
major patient predictors of early and late outcomes?
 What patients are optimally suited for TVT versus traditional surgical versus
medical management?
Device performance and safety
 How well will the technology perform in broad clinical use, i.e., “real-world” use?
 Will there be new safety issues that arise when the therapy is used in large
numbers of patients over extended periods of time; will new device failure
modes be identiﬁed?
 How do newer device iterations compare with prior ones?
Procedure performance
 In what sort of facility is the procedure optimally performed, by whom, and
associated with what type of learning curves?
 How do acute and long-term TVT outcomes vary among sites? Is there a volume
threshold for optimal outcomes?
 How will performance standards be deﬁned, the TVT registry be used to quantify
performance, and methods be distributed to improve performance of the
systems delivering the therapy?
Registry performance
 What are the lessons learned in building and executing a national
device registry?
 How well does it serve as an effective tool for conducting PAS, tracking off-label
use, and so forth?
 Can it be adapted in the future as an alternative mechanism for pre-IDE studies
by providing the infrastructure for coverage with evidence development?
Abbreviations as in Table 1.
Table 1 Transcatheter Valve Therapy Registry Overview
Composition and enrollment
 Prospective enrollment of all patients in the United States receiving
FDA-approved transcatheter heart valve devices
Registry data elements, analysis, and reporting
 Standardized and comprehensive data elements: indications, patient charac-
teristics, periprocedural results and complications, in-hospital, 30-day, and
subsequent yearly outcomes, and patient health status measures
 Harmonization of elements and deﬁnitions with national and international
registries, pivotal trials, and consensus groups (e.g., VARC) whenever possible
 Unique device identiﬁcation
 Long-term outcomes with linkages to CMS administrative claims data with
adjudication of pre-speciﬁed adverse outcomes relevant to individual devices
 Implantation hospitals responsible for data entry using web-based data entry
interface from the NCDR
 Completeness and accuracy of data entry monitored and audited both internally
(NCDR-STS) and externally (FDA)
 Protection of conﬁdential health care information and utilization of patient-
informed consent when appropriate
 Quarterly benchmarking reports for hospitals to compare the institution’s
performance with that of volume-based peer groups and the national
experience
Governance and structure
 Steering committee
 Research and publications subcommittee
 Stakeholders advisory group
Analytic centers and research
 Contracted analytic center: Duke Clinical Research Institute
 FDA-mandated PAS nested within the Registry with the ability of industry to use
this infrastructure to meet their condition of approval requirements
 IDE studies sponsored by professional societies
 Future linkages with other professional society registries and other
national registries
 Other substudies nested within the TVT registry
Funding
 STS, ACC, TVT registry site fees, medical device industry, FDA, and
research grants
ACC ¼ American College of Cardiology; CMS ¼ Center for Medicare and Medicaid Services;
FDA ¼ Food and Drug Administration; IDE ¼ investigational device exemption; NCDR ¼ National
Cardiovascular Data Registry; PAS ¼ post-approval study; STS ¼ The Society of Thoracic Surgeons;
TVT ¼ transcatheter valve therapy; VARC ¼ Valve Academic Research Consortium.
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collection of quality-of-life measures. The primary measure
will be the Kansas City Cardiomyopathy Questionnaire
(KCCQ), a valid and reliable measure of patient-reported
symptom burden, functional status, and quality of life that
is sensitive to clinical change and has been used in TAVR
patients (13).
Risk models tailored for the TVT population. Models of
outcomes will be developed and validated using TVT
registry data that will be used for benchmark comparisons of
risk-adjusted outcomes among centers, and can potentially
provide personalized risk estimates to support informed
decisions by patients and clinicians regarding the likelihood
of beneﬁts and complications.
Appropriateness of use. Data collected over years can be
analyzed for the appropriateness of the procedure correlating
patient characteristics with post-procedural outcomes. With
the procedure indications thus deﬁned, it will then be
possible to effectively monitor for potentially appropriate or
inappropriate “indication creep.”
Expansion of indications for use. The TVT registry will
gather data on device use in ways not originally intendedusing clinical research protocols imbedded in the registry.
“Valve-in-valve” (the placement of TVT valves in degen-
erated surgical bioprostheses) and alternative vascular
access (i.e., transapical, transaortic, trans-subclavian, and
transiliac) are uses of TAVR technology not part of FDA-
approved indications from November 2011 and not
covered by the CMS national coverage decision (NCD)
from May 2012 for the Sapien valve use in inoperable
patients. Part B of the CMS NCD provides reimbursement
of procedures performed as part of a CMS-approved
research study (14). After months of developing a new
model for a TVT registry-based IDE study, the STS and
ACC submitted to CMS and FDA a research proposal to
study alternative access for inoperable patients. The FDA
has recently approved the IDE study (G120291); the
clinical trial number has been issued (NCT01787084); CMS
has approved the research proposal; and the study will soon
be initiated and be open to all qualifying and compliant
TAVR sites in the United States. This unique study is also
constructed so that the scientiﬁc evidence developed can be
used by the FDA to expand indications.
Nested PAS studies. Data for FDA-mandated PAS will
be nested within the TVT registry and will satisfy the FDA
requirements placed on the sponsor. The registry design can
accommodate differences in the scope of data collection and
operation as requested by the FDA for the sponsor. The
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studies.
Linkages to Other Registries and
Relationship to Randomized Clinical Trials
The TVT registry is a registry focused on new trans-
catheter technologies, is not a comprehensive disease-based
registry, and, by itself, cannot be used to compare treat-
ment alternatives or to establish appropriateness or one
treatment versus another. Links can and will be made to
the STS Adult Cardiac Surgery Database to compare open
surgical techniques to TVT techniques. For other patients
who have neither surgery nor TVT, there will be the need
to gather data on medical management from PINNACLE
(Practice Innovation and Clinical Excellence), a NCDR
registry of out-patient quality improvement, or other
sources.
Registries, such as the TVT registry, can support obser-
vational studies but are not a substitute for randomized
clinical trials (RCT) when needed to control for selection
bias. However, the network of hospitals involved in the TVT
registry may be useful for the recruitment and conduct of
RCTs. Data from the TVT registry may be helpful in
planning RCTs, and/or may be useful within an RCT
conducted using the TVT registry sites/infrastructure,
leading to a more efﬁcient clinical trial.Figure 1 TVT Registry Is Placed in Context of Process of Device Eva
The dotted vertical line represents the time when Food and Drug Administration (FDA) a
developed to monitor results of established procedures. The transcatheter valve therapy
There are plans to potentially expand the TVT registry into the pre-PMA period to further brin
approval phases of device evaluation. PMA ¼ premarket approval; RCT ¼ randomized cliThe TVT Registry Deﬁned
The TVT registry is placed in the context of the FDA’s
medical device regulatory process (Fig. 1) and is a next
generation of prospective registries implemented with the
introduction of new technologies into real-world practice.
Initially, the registry will contain data on only 1 TAVR
device but it eventually can include all future approved
technologies in the TVT domain.
The TVT registry is a national registry in the United
States. More than 50,000 TAVR procedures have been
completed after commercial release in 46 countries world-
wide. Reports in 2011 from registries in Canada (15), Italy
(16), Germany (17), France (18), and the United Kingdom
(19) included 2,817 patients. Subsequently, in 2012, the
German Registry (GARY) has been described in detail
with >15,000 datasets entered (20). Most recently, the
Transcatheter Valve Treatment Sentinel Pilot Registry, a
prospective independent consecutive registry, reported 4,571
patients undergoing TAVI between January 2011 and
May 2012 in 137 medical centers of 10 European countries
(21) The groundwork for TVT worldwide registries has
been laid.
In a paradigm shifting approach to surveillance, the FDA
has recently initiated efforts to facilitate and promote the
development of international registry consortia with the goal
to augment the infrastructure for evidence generation,luation Leading to and After FDA Approval
pproval occurs. Previous clinical registries run by professional societies have been
(TVT) registry will prospectively capture patients immediately after device approval.
g data element standardization and efﬁcient transitions from the pre-approval to post-
nical trial.
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outcomes throughout the product life cycle. Notably, in
2011, the International Consortium of Orthopedic Regis-
tries was created, consisting of 29 orthopedic registries from
14 nations and capturing 3.5 million procedures involving
orthopedic implants worldwide (22). The FDA also initiated
efforts to develop an international consortia of cardiovascular
registries (23).
The TVT registry is listed in the U.S. National Institutes
of Health clinicaltrials.gov (NCT01737528) as part of this
database of clinical studies conducted worldwide.
Patient Composition and
Enrollment in the TVT Registry
In the past, studies reported from some registries were
difﬁcult to interpret because of potential selection bias and
lack of knowledge of the overall population. The TVT
registry with its expected inclusion of most, if not all, treated
patients in the United States should eliminate this concern.
Several factors will likely result in a high rate of enroll-
ment. The CMS NCD includes a requirement that TAVR
will be covered for Medicare beneﬁciaries only if the patient
is enrolled in a prospective national registry (14). Further-
more, institutions need a site-speciﬁc analysis of their
programs compared to benchmarks from a nationwide
experience. PAS studies may be required to use a nationalFigure 2 Cumulative TVT Registry Sites Enrolled From January 2012
The graph depicts the number of hospitals enrolled in the transcatheter valve therapy (TV
aortic valve replacement sites in the United States. The process of enrollment can take
complete the process soon. ACC ¼ American College of Cardiology; NCDR ¼ National Caregistry. Figure 2 shows the growth of formal participation
of the TVT registry, and Figure 3 shows the number of
patient records submitted from the initial TAVR procedure.
As of August 7, 2013 there have been 245 sites in the
United States formally enrolled in the TVT registry.
Clinical registry data collection is considered a part of
an institution’s quality assessment and improvement process
and therefore does not require speciﬁc written informed
patient consent. The TVT registry complies with the rele-
vant regulations relating to the protection of human research
subjects, and this protocol is part of the TVT registry that
has undergone and had been given approval by an inde-
pendent institutional review board review from Chesapeake
Research Review Inc. There is no added procedural risk to
patients through involvement in the TVT registry. Patient
data used in potentially CMS-approved studies on such
topics as valve-in-valve and alternative access approaches are
collected using only data elements included in the original
TVT registry and undergoing variations in the use of TAVR
as decided by the clinicians caring for the patients. No risk or
procedures beyond those required for routine care will be
imposed. Conversely, if the goal of such studies is to expand
a device’s indication, then a formal IDE may be necessary;
and this carries additional responsibilities and compliance
issues that have been the subject of extensive discussions
between the TVT registry and the FDA. Finally, partici-
pation in a speciﬁc prospective, FDA-regulated PAS mayto Beginning August 2013
T) registry during 2012 plus mid 2013 and represents nearly all active transcatheter
some time for hospitals to complete, and the few remaining sites are expected to
rdiovascular Data Registry; STS ¼ The Society of Thoracic Surgeons.
Figure 3 Cumulative TVT Records May 2012 to Beginning August 2013
Patients who have undergone transcatheter aortic valve replacement and have had their data entered into the transcatheter valve therapy (TVT) registry during 2012 plus mid
2013 are plotted as a function of month of data submission for their procedure. Acceleration of entries occurred after the national coverage decision from the Center for
Medicare and Medicaid Services announced the reimbursement requirements that included registry participation. Sites are still entering their backlog of completed cases. As of
August 7, 2013 there were 8,108 patient records entered. Abbreviations as in Figure 2.
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informed consent if the PAS involves collecting speciﬁc
elements of personal health information or data for research
purposes.
Registry Data Elements
The TVT registry data collection form and dictionary are
available at the TVT registry website (www.tvtregistry.org).
Version 1.1 has online data entry that became active in
July 2012.
Although TAVR technology has led to some unique data
elements, most elements and deﬁnitions are commonly
included in other clinical registries. In the design of the
TVT registry, particular attention was given to data elements
and deﬁnitions that are harmonized with TAVR trials. The
Valve Academic Research Consortium is a multiple stake
holder group that has created consistent endpoint deﬁnitions
and consensus recommendations for TAVR clinical research
programs (24–26). These efforts have been valuable to the
TVT registry focused on use of these technologies in real-
world settings.
Echocardiographic data post-TAVR are also important
parameters that will be captured in the TVT registry to
assess prosthetic durability, but are currently not incorpo-
rated in clinical management guidelines (27).Data Entry, Monitoring, and Auditing
Participating sites will submit complete periprocedural and
short-term follow-up data on all patients who undergo a
TAVR procedure. Outcomes beyond the ﬁrst year will be
captured through linkage with the CMS database.
The TVT registry will have an extensive data quality
program including multiple mechanisms to monitor com-
pleteness and accuracy. These include site training and sup-
port by TVT registry staff, data “cleaning” by data integrity
checks utilizing range validation and other measures, auditing
at the site level portions of data, and adjudication of selected
30-day and 1-year outcomes. Collection of source documents
and veriﬁcation of pre-speciﬁed key events can be added
speciﬁcally for PAS studies. Audit strategies will be executed
by the FDA for the TVT registry. The Duke Clinical
Research Institute will also provide event adjudication services
for pre-speciﬁed events and other operational support.Reporting
The TVT registry will provide feedback to sites including
quarterly quality national benchmarking. Participants will
have access to a repository of their own data and tools to
evaluate their local practice and conduct user-speciﬁed local
data queries. Heart teams will be encouraged to review
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The TVT registry will also issue annual reports at profes-
sional meetings of TAVR and future TVT technology
that will include volume and outcomes. CMS-approved
studies as described in part B of the NCD will be reported
as speciﬁed in the protocol. The PAS studies will be re-
ported as determined by its research and publications
committee.
Funding
The investment to enable the creation of the TVT registry
began 2 decades ago as STS and ACC founded their
respective national clinical databases. The development of
the TVT registry has been funded by STS and ACC. The
on-going funding must maintain the independence of the
governance and day-to-day activities of the registry.
Funding for operational expenses associated with TVT
registry will predominantly be from site fees, namely, paid
for by institutions with TVT programs. The FDA will
provide some resources for monitoring the quality of data
entered by sites through audits, particularly associated with
PAS studies. Device PAS studies that are nested within the
TVT registry will be appropriately funded by the sponsor.
Investigator-initiated research will be able to access the
data in the TVT registry with funding from private and
public agencies. Funding for IDE studies may include
support from industry, but strict ﬁrewalls have been placed
to maintain the independence, impartiality, and scientiﬁc
credibility of the professional societies in designing,
conducting, and reporting trials. Both ACC and STS have
formal rules for engagement with industry involving
data use, scientiﬁc integrity, governance, marketing, and
promotion (29–32).
Governance
The primary independent governing body is a steering
committee of representatives from STS and ACC. Repre-
sentatives from the Duke Clinical Research Institute, the
National Heart, Lung, and Blood Institute, the FDA, and
the CMS are nonvoting ex-ofﬁcio members of the steering
committee. The steering committee shall provide strategic
direction for the TVT registry, monitor all activities, and
have ultimate authority and responsibility for the scientiﬁc
integrity and appropriate use of the TVT registry data for
research and publications.
The research and publications subcommittee will oversee
all activities related to research and publications using TVT
registry data. Industry-sponsored PAS will have a sepa-
rate research and publications committee. All committee
members are required to submit relationship with industry
information.
The stakeholder advisory group will provide input, guid-
ance, and feedback to the steering committee on pertinent
clinical and scientiﬁc topics. Members selected by the steeringcommittee will represent stakeholders, including govern-
ment entities, patient advocates, device manufacturers, and
insurers.
Challenges for the TVT Registry
The principle challenges of the TVT registry include
demonstration of its added value versus maintaining the
status quo, justifying the burden of data collection, validating
the completeness and quality of data, and being a profes-
sional “good shepherd” of using these data for objective,
bias-free, and scientiﬁcally based reports. Furthermore, the
TVT registry must be linked to other professional registries
to enhance the efﬁciency of data entry, reduce redundancies,
and to enable comparative effectiveness research and regu-
latory decision making.
National clinical registries are becoming part of the cost to
offer high-end therapies such as ventricular assist devices,
implantable deﬁbrillators, and now TAVR. The burdens
associated with entering high-quality data from hospitals are
recognized and potentially will be reduced with medical
information technology infrastructure improvements.
The costs of the TVT registry will need to be periodically
assessed with transparency of the expenses and demonstration
of the value of the deliverables. For industry, the transition
from the prior PASmodel to the use of the TVT registry must
also have an on-going evaluation and process of improvement.
The structure and governance of the TVT registry provides
for this process and involvement of industry.
The quality of the data in the TVT registry is a top
priority, and the means to monitor, audit, and adjudicate
have been outlined. The reliance on CMS administrative
data for longitudinal outcomes must be further studied. The
implementation of novel and potentially more efﬁcient
means of event adjudication must be assessed in peer-
reviewed scientiﬁc publications. New challenges are ex-
pected in implementing and optimizing the new pathway for
clinical protocols that will provide CMS reimbursement and
gather data for potential FDA decisions to expand indica-
tions for use of an approved device. This replaces the prior
system of “off-label” use of devices with no pre-speciﬁed
data collection and analysis, no pathway to potential
expansion of indications, and challenges to the reimburse-
ment and regulatory systems.
While a rational dispersion of new technology is appro-
priate, there are many unexplored and potentially unintended
consequences of this new model of novel technology disper-
sion and centrally based control. For example, the need for
a CMS-approved research protocol to allow use of an alter-
native access site to place an approved TAVR device starts to
cross into the traditional realm of clinician control of proce-
dural techniques. The CMS and FDA controlled research
protocol pathway for the use of new approved technologies in
narrowly deﬁned off-label uses may result in more frequent
appropriate use with a better understanding of these appli-
cations from registry-based data collection and analysis, but
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minimized. Finally, there will always be outliers not covered
by research protocols for common off-label uses. The chal-
lenge is signiﬁcant to reﬁne this new model to optimize
rational device dispersion, appropriate reimbursement, and
effective regulation without compromising the need for
clinicians and patients to individualize care within the broad
context of scientiﬁc evidence presented in guidelines derived
from population-based recommendations.
Future Perspective
The TVT registry is an ambitious undertaking with a
potential to have a major impact on patient health care and
safety, clinical research, evaluation throughout the device life
cycle , and informed decision making by clinicians, patients,
policy makers, payers, and regulators. Successful imple-
mentation of this model can be replicated broadly in other
medical specialties and other areas of medical care. The
TVT registry has been developed and implemented in the
midst of on-going developments in the FDA’s vision for the
novel approaches to medical device evidence generation,
synthesis, and evaluation, CMS’s deliberations on national
coverage decisions, and the medical device industry’s adap-
tation to these changes (33,34). The data infrastructure
created offers the ability to catalyze the joint initiatives of
CMS and FDA (35). The professional societies have also
embraced a new level of responsibility in coordinating and
implementing these changes as well as being the voice and
advocate of patients and clinicians. The launch of the TVT
registry is only the beginning of a new model that will be
reﬁned and improved in the years to come.
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